000088257 001__ 88257
000088257 005__ 20200716101608.0
000088257 0247_ $$2doi$$a10.1038/s41598-019-55765-9
000088257 0248_ $$2sideral$$a116436
000088257 037__ $$aART-2019-116436
000088257 041__ $$aeng
000088257 100__ $$aLopez-Tarruella, S
000088257 245__ $$aSurvival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
000088257 260__ $$c2019
000088257 5060_ $$aAccess copy available to the general public$$fUnrestricted
000088257 5203_ $$aThe debate about surgical resection of primary tumor (PT) in de novo metastatic breast cancer (MBC) patients persists. We explored this approach''s outcomes in patients included in a retrospective registry, named El Alamo, of breast cancer patients diagnosed in Spain (1990-2001). In this analysis we only included de novo MBC patients, 1415 of whom met the study''s criteria. Descriptive, Kaplan-Meier and Cox regression analyses were carried out. Median age was 63.1 years, 49.2% of patients had single-organ metastasis (skin/soft tissue [16.3%], bone [33.8%], or viscera [48.3%]). PT surgery (S) was performed in 44.5% of the cases. S-group patients were younger, had smaller tumors, higher prevalence of bone and oligometastatic disease, and lower prevalence of visceral involvement. With a median follow-up of 23.3 months, overall survival (OS) was 39.6 versus 22.4 months (HR = 0.59, p < 0.0001) in the S- and non-S groups, respectively. The S-group OS benefit remained statistically and clinically significant regardless of metastatic location, histological type, histological grade, hormone receptor status and tumor size. PT surgery (versus no surgery) was associated with an OS benefit suggesting that loco-regional PT control may be considered in selected MBC patients. Data from randomized controlled trials are of utmost importance to confirm these results.
000088257 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000088257 590__ $$a3.998$$b2019
000088257 591__ $$aMULTIDISCIPLINARY SCIENCES$$b17 / 71 = 0.239$$c2019$$dQ1$$eT1
000088257 592__ $$a1.341$$b2019
000088257 593__ $$aMultidisciplinary$$c2019$$dQ1
000088257 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000088257 700__ $$aEscudero, MJ
000088257 700__ $$aPollan, M
000088257 700__ $$aMartin, M
000088257 700__ $$aJara, C
000088257 700__ $$aBermejo, B
000088257 700__ $$aGuerrero-Zotano, A
000088257 700__ $$aGarcia-Saenz, J
000088257 700__ $$aSantaballa, A
000088257 700__ $$aAlba, E
000088257 700__ $$0(orcid)0000-0003-0123-4274$$aAndres, R$$uUniversidad de Zaragoza
000088257 700__ $$aMartinez, P
000088257 700__ $$aCalvo, L
000088257 700__ $$aFernandez, A
000088257 700__ $$aBatista, N
000088257 700__ $$aLlombart-Cussac, A
000088257 700__ $$aAnton, A
000088257 700__ $$aLahuerta, A
000088257 700__ $$ade la Haba, J
000088257 700__ $$aLopez-Vega, JM
000088257 700__ $$aCarrasco, E
000088257 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000088257 773__ $$g9 (2019), 20081 [12 pp.]$$pSci. rep.$$tScientific Reports$$x2045-2322
000088257 8564_ $$s2666446$$uhttps://zaguan.unizar.es/record/88257/files/texto_completo.pdf$$yVersión publicada
000088257 8564_ $$s229439$$uhttps://zaguan.unizar.es/record/88257/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000088257 909CO $$ooai:zaguan.unizar.es:88257$$particulos$$pdriver
000088257 951__ $$a2020-07-16-09:55:30
000088257 980__ $$aARTICLE